The Protective Role of PGC‐1α in Cystitis Glandularis: Mitigating Mitochondrial Injury and Inflammation
International Journal of Clinical Practice · 2024-01 · 2024 (1)
DOI: 10.1155/ijcp/8164243 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Practice, online erschienen am 25.12.2024. Verfasst von Min Chen und 8 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Guangxi Province.
Abstract (Originalsprache)
Background
Peroxisome proliferator‐activated receptor‐gamma coactivator‐1α (PGC‐1α), a regulator of mitochondrial function, plays a critical role in inflammation and may be involved in cystitis glandularis (CG) development.
Methods
LPS was administered to establish a CG model in female Sprague–Dawley (SD) rats and to induce cellular injury in the human urothelial cell line SV‐HUC‐1. Subsequently, to elucidate the role of PGC‐1α signaling in CG, both the animal and cellular models were treated with ZLN005, a specific activator of PGC‐1α. Cell viability was assessed using the cell‐counting kit‐8 (CCK8) assay. Mitochondrial damage was quantified by measuring reactive oxygen species (ROS), assessing mitochondrial membrane potential, and examining mitochondrial ultrastructure via transmission electron microscopy (TEM). Enzyme‐linked immunosorbent assays (ELISA) were utilized to determine the levels of inflammatory cytokines, namely, IL‐1β, IL‐6, and TNF‐α. Furthermore, the protein expression of silent information regulation 1 (SIRT1), PGC‐1α, mitochondrial transcription factor A (TFAM), nuclear respiratory factor 1 (NRF1), and nuclear respiratory factor 2 (NRF2) was evaluated using immunohistochemistry and/or Western blot analysis.
Results
LPS‐treated rat bladder exhibited histological characteristics of CG, including increased urothelial proliferation and inflammation. PGC‐1α protein levels were downregulated in human CG tissues, LPS‐treated rat bladders, and SV‐HUC‐1 cells. Mitochondrial damage was observed in both rat CG and LPS‐irritated cells with elevated ROS and diminished mitochondrial membrane potential. TEM documented mitochondrial morphological injury of the urothelium in rat CG. ZLN005 attenuated LPS‐induced epithelial hyperplasia and inflammatory cytokine secretion in the rat CG model. Furthermore, ZLN005 partially reversed LPS‐induced mitochondrial damage, as indicated by reduced ROS levels, restored mitochondrial membrane potential, and mitigated mitochondrial morphological injury in both rat CG and LPS‐stimulated cells. In addition, ZLN005 restored the expression of PGC‐1α and its associated signaling proteins SIRT1, TFAM, NRF1, and NRF2.
Conclusions
The downregulation of PGC‐1α suggests its potential as a molecular marker for the progression of CG. Targeting the PGC‐1α signaling pathway may offer an effective therapeutic intervention for the clinical management of CG.
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province
Zitieren
APA
Chen, M., Tang, Y., Fu, Y., Hu, H., Cui, E., Wen, Z., Zhong, W., Su, J., & Ge, B. (2024). The Protective Role of PGC‐1α in Cystitis Glandularis: Mitigating Mitochondrial Injury and Inflammation. International Journal of Clinical Practice, 2024(1). https://doi.org/10.1155/ijcp/8164243
Vancouver
Chen M, Tang Y, Fu Y, Hu H, Cui E, Wen Z, et al. The Protective Role of PGC‐1α in Cystitis Glandularis: Mitigating Mitochondrial Injury and Inflammation. International Journal of Clinical Practice. 2024;2024(1). doi:10.1155/ijcp/8164243
BibTeX
@article{Chen2024,
author = {Chen, Min and Tang, Yongbo and Fu, Yue and Hu, Haiwei and Cui, Ende and Wen, Zhouliang and Zhong, Wei and Su, Jimin and Ge, Bo},
title = {The Protective Role of PGC‐1α in Cystitis Glandularis: Mitigating Mitochondrial Injury and Inflammation},
journal = {International Journal of Clinical Practice},
year = {2024},
volume = {2024},
number = {1},
doi = {10.1155/ijcp/8164243}
}
EUVIMED